Literature DB >> 27551808

Vaccine adjuvants: Why and how.

Dennis Christensen1.   

Abstract

Novel vaccine strategies include the so-called subunit vaccines, which encompass only the part of the pathogen to which immune recognition results in protection. The high purity of these vaccines make adverse events less likely, but it also makes the vaccines less immunogenic and therefore potentially less effective. Vaccine adjuvants that increase and modulate the immunogenicity of the vaccine are therefore added to solve this problem. Besides aluminum salts, which have been used in vaccines for 90 years, a number of novel vaccine adjuvants have been included in licensed vaccines over the last 30 years. Increasing insight into immunological mechanisms and how to manipulate them has replaced empirical with rational design of adjuvants, leading to vaccine adjuvants with increased and customized immunogenicity profiles without compromising vaccine safety.

Entities:  

Keywords:  adjuvant; immunogenicity; immunostimulators; sub-unit; vaccine

Mesh:

Substances:

Year:  2016        PMID: 27551808      PMCID: PMC5084984          DOI: 10.1080/21645515.2016.1219003

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  8 in total

Review 1.  New technology platforms in the development of vaccines for the future.

Authors:  R Glück; I C Metcalfe
Journal:  Vaccine       Date:  2002-12-20       Impact factor: 3.641

Review 2.  The history of MF59(®) adjuvant: a phoenix that arose from the ashes.

Authors:  Derek T O'Hagan; Gary S Ott; Gary Van Nest; Rino Rappuoli; Giuseppe Del Giudice
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

3.  A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.

Authors:  Jaap T van Dissel; Simone A Joosten; Søren T Hoff; Darius Soonawala; Corine Prins; David A Hokey; Dawn M O'Dee; Andrew Graves; Birgit Thierry-Carstensen; Lars V Andreasen; Morten Ruhwald; Adriëtte W de Visser; Else Marie Agger; Tom H M Ottenhoff; Ingrid Kromann; Peter Andersen
Journal:  Vaccine       Date:  2014-10-30       Impact factor: 3.641

4.  Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers.

Authors:  Jaap T van Dissel; Sandra M Arend; Corine Prins; Peter Bang; Pernille Nyholm Tingskov; Karen Lingnau; Jan Nouta; Michèl R Klein; Ida Rosenkrands; Tom H M Ottenhoff; Ingrid Kromann; T Mark Doherty; Peter Andersen
Journal:  Vaccine       Date:  2010-03-11       Impact factor: 3.641

Review 5.  Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.

Authors:  Woolf T Walker; Saul N Faust
Journal:  Expert Rev Vaccines       Date:  2010-12       Impact factor: 5.217

6.  Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.

Authors: 
Journal:  Lancet       Date:  2015-04-23       Impact factor: 79.321

Review 7.  Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix].

Authors:  Susan J Keam; Diane M Harper
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting.

Authors:  Adam Penn-Nicholson; Hennie Geldenhuys; Wivine Burny; Robbert van der Most; Cheryl L Day; Erik Jongert; Philippe Moris; Mark Hatherill; Opokua Ofori-Anyinam; Willem Hanekom; Anne Bollaerts; Marie-Ange Demoitie; Angelique Kany Kany Luabeya; Evi De Ruymaeker; Michele Tameris; Didier Lapierre; Thomas J Scriba
Journal:  Vaccine       Date:  2015-06-10       Impact factor: 3.641

  8 in total
  19 in total

1.  CARD9-Associated Dectin-1 and Dectin-2 Are Required for Protective Immunity of a Multivalent Vaccine against Coccidioides posadasii Infection.

Authors:  Althea Campuzano; Hao Zhang; Gary R Ostroff; Lucas Dos Santos Dias; Marcel Wüthrich; Bruce S Klein; Jieh-Juen Yu; Humberto H Lara; Jose L Lopez-Ribot; Chiung-Yu Hung
Journal:  J Immunol       Date:  2020-05-01       Impact factor: 5.422

2.  Impact of the Charge Ratio on the In Vivo Immunogenicity of Lipoplexes.

Authors:  Zahra Heidari; Jaspreet S Arora; Dibyadyuti Datta; Vijay T John; Nirbhay Kumar; Geetha P Bansal
Journal:  Pharm Res       Date:  2017-05-30       Impact factor: 4.200

Review 3.  Developments in Vaccine Adjuvants.

Authors:  Farrhana Ziana Firdaus; Mariusz Skwarczynski; Istvan Toth
Journal:  Methods Mol Biol       Date:  2022

Review 4.  Insights into COVID-19 vaccines development: Translation from benchside to bedside.

Authors:  Marwa Houssein; Aya El Asir Al Hossainy; Jana Al Soussi; Jana El Batch; Lana El-Samadi; Sherine El Imam; Rawan Fakih; Hoda Dakdouk; Mahmoud Khalil
Journal:  Health Sci Rev (Oxf)       Date:  2022-07-10

Review 5.  Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus.

Authors:  Patricia A Jorquera; Ralph A Tripp
Journal:  Vaccines (Basel)       Date:  2016-12-02

6.  An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein.

Authors:  Fatemeh Ghafouri; Reza Ahangari Cohan; Farshid Noorbakhsh; Hilda Samimi; Vahid Haghpanah
Journal:  Res Sq       Date:  2020-05-20

7.  Antivaccine Messages on Facebook: Preliminary Audit.

Authors:  Dhamanpreet Dhaliwal; Cynthia Mannion
Journal:  JMIR Public Health Surveill       Date:  2020-10-20

8.  Comprehensive Analysis of the Safety Profile of a Single-Stranded RNA Nano-Structure Adjuvant.

Authors:  Hyeong-Jun Park; Hae Li Ko; Dong-Hoon Won; Da-Bin Hwang; Yoo-Sub Shin; Hye-Won Kwak; Hye-Jung Kim; Jun-Won Yun; Jae-Hwan Nam
Journal:  Pharmaceutics       Date:  2019-09-07       Impact factor: 6.321

Review 9.  Vaccine Adjuvants Derived from Marine Organisms.

Authors:  Nina Sanina
Journal:  Biomolecules       Date:  2019-08-03

10.  Cricket paralysis virus internal ribosome entry site-derived RNA promotes conventional vaccine efficacy by enhancing a balanced Th1/Th2 response.

Authors:  Hye Won Kwak; Hyo-Jung Park; Hae Li Ko; Hyelim Park; Min Ho Cha; Sang-Myeong Lee; Kyung Won Kang; Rhoon-Ho Kim; Seung Rok Ryu; Hye-Jung Kim; Jae-Ouk Kim; Manki Song; Hun Kim; Dae Gwin Jeong; Eui-Cheol Shin; Jae-Hwan Nam
Journal:  Vaccine       Date:  2019-07-29       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.